GlassScriptPhysician profile
Charles R Ducombs
NPI 1891765954
$1,271.38
in general payments reported to CMS, 2019-2025
29 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $95.25 · 2023: $333 · 2024: $176 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169.93 | 2023-2025 | Viberzi, Linzess, Synthroid |
| Glaxosmithkline, LLC. | $154.92 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $140.97 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $97.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.10 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $75.04 | 2019 | |
| Novo Nordisk INC | $67.15 | 2019-2025 | |
| Smith+Nephew, INC. | $44.50 | 2019-2020 | |
| Abbott Laboratories | $42.62 | 2023-2024 | Freestyle Libre |
| Allergan, INC. | $34.90 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34.16 | 2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.18 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $25.90 | 2019 | |
| Lilly USA, LLC | $25.25 | 2019-2025 | Zepbound, Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.26 | 2025 | Camzyos |
| Dexcom, INC. | $21.24 | 2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $18.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.29 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.43 | 2025 | Xifaxan |
| Amgen INC. | $16.19 | 2025 | Evenity |
| Genentech USA, INC. | $15.10 | 2019 | |
| Sumitomo Pharma America, INC. | $15.03 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $14.29 | 2023 | Nexletol |
| Amarin Pharma, INC. | $13.62 | 2019 | |
| Boston Scientific Corporation | $13.53 | 2023 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $11.05 | 2025 | Voquezna |
| Beta Bionics, INC. | $8.41 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ducombs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.